Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Abstract Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low levels by 6 months, and homologous and heterologous booster immunization programs have been implemented in adults in China. The booster immunization of rec...

Full description

Bibliographic Details
Main Authors: Tao Huang, Qianqian Hu, Xiang Zhou, Huaiyu Yang, Wei Xia, Feng Cao, Minglu Deng, Xiaoxue Teng, Fan Ding, Zaixin Zhong, Lidong Gao, Jiufeng Sun, Lihui Gong
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Infectious Diseases
Subjects:
COVID-2019
SARS-CoV-2
Vaccine
Safety
Immunogenicity
Booster immunization
Online Access:https://doi.org/10.1186/s12879-024-09293-1

Internet

https://doi.org/10.1186/s12879-024-09293-1

Similar Items